BEAM Q3 2024 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M-17.0% YoY

Gross Profit

-$80M-560.6% margin

Operating Income

-$107M-746.4% margin

Net Income

-$97M-677.5% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+21.2%

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$90M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$380M

Stockholders' Equity

$791M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$17M	-17.0%
Gross Profit	-$80M	-$83M	+3.5%
Operating Income	-$107M	-$108M	+1.6%
Net Income	-$97M	-$96M	-0.6%